\nAllurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales.<\/p>\n
\n\u201cWe are thrilled the Allurion Balloon will once again serve French patients as a clinically proven treatment for obesity,\u201d said Dr. Shantanu Gaur, Founder and CEO of Allurion. \u201cHistorically, France has been our top performing market representing approximately 15% of our revenue, and we are looking forward to ramping back up in the coming quarters.<\/p>\n
\n\u201cIn parallel, as we expand our clinical research pipeline, we are also exploring with French clinics a trial to demonstrate how the Allurion Balloon may be combined with GLP-1s to solve one of the biggest problems in obesity: how to take GLP-1s without losing muscle mass. A successful trial could lead to the development of a gold-standard obesity treatment that counters one of the biggest side effects of GLP-1 therapies.\u201d<\/p>\n
\nAccording to a recent study, the prevalence of excess weight and obesity in France is approximately 47% and 17%, respectively.1<\/sup> While current-generation GLP-1s have now launched in France, their use has primarily been indicated as a second-line treatment in patients with a body mass index (BMI) of greater than or equal to 35 with careful attention to side effect management.2<\/sup> Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.3<\/sup><\/p>\n \nIn contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight over four months.4<\/sup> In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass.<\/p>\n \n\u201cWe intend to initiate clinical trials designed to assess whether the Allurion Balloon combined with GLP-1s offers superior outcomes to GLP-1 therapies alone,\u201d continued Gaur. \u201cWe intend for our first clinical trials to study muscle mass in a combination approach, but we expect to announce other clinical trials in the future that will study dose reduction of GLP-1s as a means to reduce side effects and increase adherence.\u201d<\/p>\n About Allurion<\/b><\/p>\n \nAllurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world\u2019s first and only swallowable, procedure-lessTM<\/sup> gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250212202917\/en\/1755824\/3\/Allurion_logo_HD.jpg\"){kind=logo}
<\/td>\n<\/tr>\n